




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 9, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
July 9, 2004	
Date	Mark B. Wilson

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/801,982 entitled "PROCESS AND REAGENTS FOR EXTRACTION OF RNA FROM FRACTIONATED BLOOD LEUKOCYTES" – Marianna Goldrick*
Our reference: AMBI:094US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C33.


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:094US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Marianna Goldrick

Serial No.: 10/801,982


Filed: March 16, 2004

For: PROCESS AND REAGENTS FOR
EXTRACTION OF RNA FROM
FRACTIONATED BLOOD
LEUKOCYTES

Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: AMBI:094US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
July 9, 2004	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:094US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson

Reg. No. 37,259

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 9, 2004

Form PTO-1449 (modified)

Atty. Docket No.

AMBI:094US

Serial No.

10/801,982

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Marianna Goldrick

Filing Date:

March 16, 2004

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alcorta <i>et al.</i> , "Microarray studies of gene expression in circulating leukocytes in kidney disease," <i>Exp Nephrol</i> , 10:139-149, 2002.
	C2	Alizadeh <i>et al.</i> , "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling," <i>Nature</i> , 403:503-511, 2000.
	C3	Chomczynski P and Sacchi N., "Single-step method of RNA isolation by acid guanidinium phenol chloroform extraction," <i>Anal. Biochemistry</i> , 162:156-159, 1987.
	C4	Claes <i>et al.</i> , "Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2," <i>Genes Chromosomes Cancer</i> , 37:314-320, 2003.
	C5	Cummings CA and Relman DA., "Using DNA microarrays to study host-microbe interactions," <i>Emerg Infect Disease</i> , 6:513-525, 2000.
	C6	Duvigneau <i>et al.</i> , "Delay in processing porcine whole blood affects cytokine expression," <i>J Immunological Methods</i> , 272:11-21, 2003.
	C7	Ebner <i>et al.</i> , "Generation of large numbers of human dendritic cells from whole blood passaged through leukocyte removal filters: an alternative to standard buffy coats" <i>J. Immunol Methods</i> , 252:93-104 2001.
	C8	Grace <i>et al.</i> , "Real-time quantitative RT-PCR assay of GADD45 gene expression changes as a biomarker for radiation biodosimetry," <i>Int'l Journal of Radiation Biology</i> , 78:1011-21, 2002.

25418919.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. AMBI:094US	Serial No. 10/801,982
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Marianna Goldrick	
		Filing Date: March 16, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Guhaniyogi J and Brewer G., "Regulation of mRNA stability in mammalian cells," <i>Gene</i> 265:11-23, 2001.
	C10	Härtel <i>et al.</i> , "Ex vivo induction of cytokine mRNA expression in human blood samples" <i>J Immunological Methods</i> , 249:63-71, 2001.
	C11	Haskill <i>et al.</i> , "Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes," <i>J Immunol.</i> , 140:1690-1694, 1988.
	C12	Hodge <i>et al.</i> , "IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression," <i>J Immunol.</i> , 168:6090-6098, 2002.
	C13	Kaufman, "Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line," <i>Cancer Res.</i> , 51:1129-1136, 1991.
	C14	Macfarlane DE and Dahle CE., "Isolating RNA from clinical samples with Catrimox-14 and lithium chloride," <i>J. Clin. Lab. Anal.</i> , 11:132-139, 1997.
	C15	Magalhaes <i>et al.</i> , "RNA synthesis inhibitors on young rat adrenal in primary culture. An ultrastructural study," <i>Tissue Cell</i> , 19:167-175, 1987.
	C16	Moenner <i>et al.</i> , "Secretion of ribonucleases by normal and immortalized cells grown in serum-free culture conditions," <i>In vitro Cell Dev. Biol. Anim.</i> , 33:553, 1997.
	C17	Pahl A and Brune K., "Stabilization of gene expression profiles in blood after phlebotomy," <i>Clinical Chemistry</i> , 48:2251-2253, 2002.
	C18	Raghavan <i>et al.</i> , "Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes," <i>Nucleic Acid Res.</i> , 30:5529-5538, 2002.
	C19	Rainen <i>et al.</i> , "Stabilization of mRNA expression in whole blood samples," <i>Clinical Chemistry</i> , 48:1883-1890, 2002.
	C20	Ross <i>et al.</i> , "Classification of pediatric acute lymphoblastic leukemia by gene expression profiling," <i>Blood</i> , 102:2951-2959, 2002.
	C21	Scheuermann RH and Racila E., "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy," <i>Leuk. Lymphoma</i> , 18:385-397, 1995.
	C22	Stahlberg <i>et al.</i> , "Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression," <i>Clinical Chemistry</i> , 49:51-59, 2003.

25418919.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. AMBI:094US	Serial No. 10/801,982
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Marianna Goldrick	
		Filing Date: March 16, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Staudt and Brown, "Genomic views of the immune system," <i>Annual Review Immunology</i> , 18:829-859, 2000.
	C24	Stordeur <i>et al.</i> , "Analysis of spontaneous mRNA cytokine production in peripheral blood," <i>J Immunol Methods</i> , 261:195-197, 2002.
	C25	Tang <i>et al.</i> , "Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease," <i>Ann Neurol.</i> 50:699-707, 2001.
	C26	Theophilus, <i>RNA Isolation and Characterization Protocols</i> , pp 39-41, edit. R. Rapley and DL Manning, Humana Press, Totowa NJ, 1998
	C27	Verdeil <i>et al.</i> , "Gene profiling approach to establish the molecular basis for partial versus full activation of naïve CD8 T lymphocytes," <i>Ann NY Acad Sci.</i> , 975:68-76, 2002.
	C28	Weitkamp JH and Crowe JE., "Blood donor leukocyte reduction filters as a source of human B lymphocytes," <i>BioTechniques</i> , 31:464-466, 2001.
	C29	Whitney <i>et al.</i> , "Individuality and variation in gene expression patterns in human blood.," <i>Proc. Natl. Acad. Sci., USA</i> , 100:1896-1901, 2003.
	C30	Xiang <i>et al.</i> , "Probe generation directly from small numbers of cells for DNA microarray studies," <i>BioTechniques</i> , 34:386-393, 2003.
	C31	Yeoh, <i>et al.</i> , "Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling," <i>Cancer Cell March</i> , 133-143, 2002.
	C32	Zhu <i>et al.</i> , "Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays," <i>Proc. Natl. Acad. Sci., USA</i> , 95:14470-14475, 1998.
	C33	"Technical Note: Globin reduction protocol: a method for processing whole blood RNA samples for improved array results," <i>Gene Expression Monitoring</i> , Affymetrix Product Family, pp 1-9.

25418919.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.